tbuckley/cabot-search huggingface dataset:
Telemonitoring Helps Keep Diabetes Under Control
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Significance Of Parameters Of Dynamic Contrast-Enhanced MRI Detecting Increased Bone Marrow Microcirculation In Monoclonal Plasma Cell Disorders
Authors: Jens Hillengass, Judith Ritsch, Maximilian Merz, Hartmut Goldschmidt, Christina Kunz, Barbara Wagner-Gund, Anthony Ho, Thomas M. Moehler, Stefan Delorme
Journal: Blood (2013)
Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients
Authors: Anneleen Lintermans, Kathleen Van Asten, Annouschka Laenen, Thomas Van Brussel, Johan Verhaeghe, Dirk Vanderschueren, Diether Lambrechts, Patrick Neven
Journal: Cancer Research (2015)
TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma
Authors: Howard A. Burris, Manish R. Patel, Danielle M. Brander, Owen A. O'Connor, Changchun Deng, Timothy S. Fenske, Martin Gutierrez, Suzanne Jones, John Kuhn, Hari P. Miskin, Peter Sportelli, Swaroop Vakkalanka, Ian Flinn
Journal: Blood (2014)
Tailoring Complex Care Management for High-Need, High-Cost Patients
Authors: David Blumenthal, Melinda K. Abrams
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Twitter as a Potential Data Source for Cardiovascular Disease Research
Authors: Lauren Sinnenberg, Christie L. DiSilvestro, Christina Mancheno, Karl Dailey, Christopher Tufts, Alison M. Buttenheim, Fran Barg, Lyle Ungar, H. Schwartz, Dana Brown, David A. Asch, Raina M. Merchant
Journal: JAMA Cardiology (2016)

<h3>Importance</h3> As society is increasingly becoming more networked, researchers are beginning to explore how social media can be used to study person-to-person communication about health and health care use. Twitter is an online messaging platform used by more than 300 million people who have generated several billion Tweets, yet little work has focused on the potential applications of these data for studying public attitudes and behaviors associated with cardiovascular health. <h3>Objective</h3> To describe the volume and content of Tweets associated with cardiovascular disease as well as the characteristics of Twitter users. <h3>Design, Setting, and Participants</h3> We used Twitter to access a random sample of approximately 10 billion English-language Tweets originating from US counties from July 23, 2009, to February 5, 2015, associated with cardiovascular disease. We characterized each Tweet relative to estimated user demographics. A random subset of 2500 Tweets was hand-coded for content and modifiers. <h3>Main Outcomes and Measures</h3> The volume of Tweets about cardiovascular disease and the content of these Tweets. <h3>Results</h3> Of 550 338 Tweets associated with cardiovascular disease, the terms<i>diabetes</i>(n = 239 989) and<i>myocardial infarction</i>(n = 269 907) were used more frequently than<i>heart failure</i>(n = 9414). Users who Tweeted about cardiovascular disease were more likely to be older than the general population of Twitter users (mean age, 28.7 vs 25.4 years;<i>P</i> &lt; .01) and less likely to be male (59 082 of 124 896 [47.3%] vs 8433 of 17 270 [48.8%];<i>P</i> &lt; .01). Most Tweets (2338 of 2500 [93.5%]) were associated with a health topic; common themes of Tweets included risk factors (1048 of 2500 [41.9%]), awareness (585 of 2500 [23.4%]), and management (541 of 2500 [21.6%]) of cardiovascular disease. <h3>Conclusions and Relevance</h3> Twitter offers promise for studying public communication about cardiovascular disease.
STRATIFICATION ACCORDING TO HGG-IMMUNO RPA MODEL PREDICTS OUTCOME IN PATIENTS WITH RELAPSED MALIGNANT GLIOMA TREATED BY ADJUVANT POSTOPERATIVE DC VACCINATION
Authors: Steven De Vleeschouwer, Hilko Ardon, Frank Van Calenbergh, Raf Sciot, Guy Wilms, Johan van Loon, Jan Goffin, Stefaan Van Gool
Journal: Neuro-Oncology (2012)
Recipient HLA-C1 Enhances The Clinical Advantage Of Killer-Cell Immunoglobulin-Like Receptor B haplotype Donors In Myeloablative Unrelated Transplantation For Acute Myelogenous Leukemia
Authors: Sarah Cooley, Daniel J. Weisdorf, Lisbeth A Guethlein, John P Klein, Tao Wang, Steve G.E. Marsh, Stephen Spellman, Michael D Haagenson, Koy Saeturn, Martha Ladner, Elizabeth Trachtenberg, Peter Parham, Jeffrey S. Miller
Journal: Blood (2013)
Building Better Systems for Stroke
Authors: Amie W. Hsia
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Authors: Marco Colonna, Oleg Butovsky
Journal: Annual Review of Immunology (2017)

Microglia are resident cells of the brain that regulate brain development, maintenance of neuronal networks, and injury repair. Microglia serve as brain macrophages but are distinct from other tissue macrophages owing to their unique homeostatic phenotype and tight regulation by the central nervous system (CNS) microenvironment. They are responsible for the elimination of microbes, dead cells, redundant synapses, protein aggregates, and other particulate and soluble antigens that may endanger the CNS. Furthermore, as the primary source of proinflammatory cytokines, microglia are pivotal mediators of neuroinflammation and can induce or modulate a broad spectrum of cellular responses. Alterations in microglia functionality are implicated in brain development and aging, as well as in neurodegeneration. Recent observations about microglia ontogeny combined with extensive gene expression profiling and novel tools to study microglia biology have allowed us to characterize the spectrum of microglial phenotypes during development, homeostasis, and disease. In this article, we review recent advances in our understanding of the biology of microglia, their contribution to homeostasis, and their involvement in neurodegeneration. Moreover, we highlight the complexity of targeting microglia for therapeutic intervention in neurodegenerative diseases.
Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial
Authors: Diederik De Cock, Rene Westhovens, Johan Joly, Sabrina Meyfroidt, Kristien Van der Elst, Patrick Verschueren
Journal: Annals of the Rheumatic Diseases (2014)
Novel oral anticoagulants for atrial fibrillation
Authors: Kamal R Mahtani, Carl Heneghan
Journal: BMJ (2016)

Successful drug treatment for tuberculosis (TB) depends on the unique contributions of its component drugs. Drug resistance poses a threat to the efficacy of individual drugs and the regimens to which they contribute. Biologically and chemically validated targets capable of replacing individual components of current TB chemotherapy are a major unmet need in TB drug development. We demonstrate that chemical inhibition of the bacterial biotin protein ligase (BPL) with the inhibitor Bio-AMS (5′-[N-(d-biotinoyl)sulfamoyl]amino-5′-deoxyadenosine) killed Mycobacterium tuberculosis (Mtb), the bacterial pathogen causing TB. We also show that genetic silencing of BPL eliminated the pathogen efficiently from mice during acute and chronic infection with Mtb. Partial chemical inactivation of BPL increased the potency of two first-line drugs, rifampicin and ethambutol, and genetic interference with protein biotinylation accelerated clearance of Mtb from mouse lungs and spleens by rifampicin. These studies validate BPL as a potential drug target that could serve as an alternate frontline target in the development of new drugs against Mtb.
Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults Following a Prodrome of Bloody Diarrhea.
Authors: Qurana F. Lewis, Deirdra R. Terrell, Bernhard Lammle, Johanna Kremer-Hovinga, James N. George, Sara K. Vesely
Journal: Blood (2004)
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis
Authors: Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Santini, Federica Sorà, Tommaso Za, Sara Marietti, Silvia Bellesi, Simona Sica, Dimitar G Efremov, Giuseppe Leone
Journal: Blood (2012)
Early weight loss is not caused by dysphagia in non-small cell lung cancer patients treated with concurrent chemoradiotherapy
Authors: Celine M Op den Kamp, D de Ruysscher, Ruud M Houben, Dehing-Oberije Cary, Ramon C Langen, Emiel F Wouters, Annemie M Schols, Anne-Marie C Dingemans
Journal: Journal of Thoracic Oncology (2009)
Efficacy of erlotinib in patients (pts) with advanced non-small-cell lung cancer (NSCLC) relative to clinical characteristics: Subset analyses from the TRUST study
Authors: S. G. Allan, L. Bosquee, A. Franke, R. Pirker, G. V. Scagliotti
Journal: Journal of Clinical Oncology (2008)

8081 Background: Erlotinib is proven to prolong survival, delay symptom progression and improve quality of life for pts with advanced NSCLC (Shepherd et al, N Engl J Med 2005;353:123–32). The global, non-randomized, open-label phase IV TRUST study of erlotinib recruited over 7000 pts across 52 countries. Methods: Pts with stage IIIB/IV NSCLC who had previously failed on or were unsuitable for chemo-/radiotherapy received erlotinib 150mg/d p.o. until disease progression or unacceptable toxicity. Results: At data cut-off on October 25, 2007, data were available for 7039 pts in the study; these data were analyzed by gender, histology and smoking status. Disease control rate (DCR) and progression-free survival (PFS) are shown in the table for six subgroups. DCR was consistent across 2nd- and 3rd-line pts in all groups; only group 5 showed any statistically significant difference between 2nd-line and 3rd-line pts in terms of PFS: 12.7 wks vs 8.9 wks, respectively (p=0.0048). OS data are mature for groups 1 and 5 only; group 1 had median OS of 5.95 mos while group 5 had median OS of 5.58 mos, i.e. no difference between male and female C/FS with SqCC. Among pts with non-squamous tumors, NS appear to derive a greater clinical benefit than C/FS. Prognostic and predictive value could not be differentiated in this study as there was no control arm. Conclusions: These data confirm the results of the phase III BR.21 study, i.e. a wide range of pt subgroups can derive a clinical benefit from erlotinib. No differences were found in DCR between pts treated in 2nd and 3rd line but some subgroups may derive a greater survival benefit when receiving erlotinib 2nd line. These data indicate that pts should not be excluded from receiving erlotinib based on clinical characteristics. Group 1 (male current/ former smokers [C/FS] with squamous-cell carcinoma [SqCC]) Group 2 (male never smokers [NS] with SqCC) Group 3 (male C/FS with non-squamous tumors) Group 4 (male NS with non-squamous tumors) Group 5 (female C/FS with SqCC) Group 6 (female NS with non-squamous tumors) DCR (CR+ PR+SD), % 69 (< 1+4+65) n = 960 59 (1+13+45) n = 78 64 (<1+8+56) n = 1758 75 (2+18+56) n = 411 63 (0+4+59) n = 162 80 (2+24+54) n = 1178 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca AstraZeneca, Bayer, Eli Lilly, Roche, sanofi-aventis
DNA replication stress: a source of APOBEC3B expression in breast cancer
Authors: David W. Cescon, Benjamin Haibe-Kains
Journal: Genome biology (2016)

APOBEC cytidine deaminases have been implicated as major contributors to the mutation burden in many cancers on the basis of their mutational signature. A new experimental study sheds light on the inciting factors, linking APOBEC3B expression to oncogene- and drug-induced replication stress.
Individualized radiation dose escalation for stage I-III non-small cell lung cancer (NSCLC) based on normal tissue constraints: mature results of a phase II trial
Authors: Angela van Baardwijk, Bart Reymen, Rinus Wanders, Gerben Bootsma, Cordula Pitz, Monique Hochstenbag, Wiel Geraedts, Ragnar Lunde, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2009)
A double-blind, randomized cross-over trial of venlafaxine versus clonidine to treat hot flashes in breast cancer patients
Authors: C. Mom, C. Buijs, P. H. Willemse, H. Boezen, J. Maurer, A. Wymenga, P. Nieboer, R. S. de Jong, E. G. de Vries, M. J. Mourits
Journal: Journal of Clinical Oncology (2007)

9083 Background: Breast cancer patients who become postmenopausal due to their treatment can experience more frequent and severe hot flashes than healthy postmenopausal women. Estrogens are considered to be contra-indicated. Venlafaxine and clonidine are both used to alleviate hot flashes, with different side effects. This study compared side effects, efficacy and patient preference. Methods: In a double-blind, cross-over study women &lt;60 years, with a history of breast cancer, and experiencing at least 14 hot flashes/week were randomized to receive venlafaxine 75 mg od (and placebo bid) for 8 weeks, followed by a 2 week wash-out period, and 8 weeks of clonidine 0.025 mg bid (and placebo od) or vice versa. Hot flash frequency and hot flash score (frequency × severity) were recorded in a diary and side effects were scored using a questionnaire during the 2 nd and 8 th week of both treatment periods, and these were compared to a baseline week. Results: Sixty patients were randomized to start with venlafaxine (n=30) and clonidine (n=30), 40 completed both treatment periods. Premature treatment discontinuation occurred in 15/59 patients during venlafaxine and in 5/53 during clonidine due to side effects (p&lt;0.05). The main side effects of venlafaxine were nausea and headache, and of clonidine dry mouth. In the 8 th week of treatment women reported more loss of appetite (24% vs 4%; p=0.03) and improved sleeping (55% vs 75%; p=0.03) with venlafaxine. A =50% reduction in hot flash score was found in 21 (49%) and 26 (55%) of the patients with venlafaxine and clonidine respectively (ns). The decrease in hot flash score was most marked in the first treatment period. At study completion 20 (33%) of the patients chose to continue clonidine, and 17 (29%) preferred venlafaxine (ns), whereas 23 (38%) declined further treatment. Conclusions: Venlafaxine and clonidine are both moderately and equally effective in the reduction of hot flashes. Side effects are the main reason for discontinuation, occurring more often during treatment with venlafaxine. No significant financial relationships to disclose.
Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids?
Authors: Peter Bentzer, Donald E. Griesdale, John Boyd, Kelly MacLean, Demetrios Sirounis, Najib T. Ayas
Journal: JAMA (2016)

Fluid overload occurring as a consequence of overly aggressive fluid resuscitation may adversely affect outcome in hemodynamically unstable critically ill patients. Therefore, following the initial fluid resuscitation, it is important to identify which patients will benefit from further fluid administration.To identify predictors of fluid responsiveness in hemodynamically unstable patients with signs of inadequate organ perfusion.Search of MEDLINE and EMBASE (1966 to June 2016) and reference lists from retrieved articles, previous reviews, and physical examination textbooks for studies that evaluated the diagnostic accuracy of tests to predict fluid responsiveness in hemodynamically unstable adult patients who were defined as having refractory hypotension, signs of organ hypoperfusion, or both. Fluid responsiveness was defined as an increase in cardiac output following intravenous fluid administration.Two authors independently abstracted data (sensitivity, specificity, and likelihood ratios [LRs]) and assessed methodological quality. A bivariate mixed-effects binary regression model was used to pool the sensitivities, specificities, and LRs across studies.A total of 50 studies (N = 2260 patients) were analyzed. In all studies, indices were measured before assessment of fluid responsiveness. The mean prevalence of fluid responsiveness was 50% (95% CI, 42%-56%). Findings on physical examination were not predictive of fluid responsiveness with LRs and 95% CIs for each finding crossing 1.0. A low central venous pressure (CVP) (mean threshold <8 mm Hg) was associated with fluid responsiveness (positive LR, 2.6 [95% CI, 1.4-4.6]; pooled specificity, 76%), but a CVP greater than the threshold made fluid responsiveness less likely (negative LR, 0.50 [95% CI, 0.39-0.65]; pooled sensitivity, 62%). Respiratory variation in vena cava diameter measured by ultrasound (distensibility index >15%) predicted fluid responsiveness in a subgroup of patients without spontaneous respiratory efforts (positive LR, 5.3 [95% CI, 1.1-27]; pooled specificity, 85%). Patients with less vena cava distensibility were not as likely to be fluid responsive (negative LR, 0.27 [95% CI, 0.08-0.87]; pooled sensitivity, 77%). Augmentation of cardiac output or related parameters following passive leg raising predicted fluid responsiveness (positive LR, 11 [95% CI, 7.6-17]; pooled specificity, 92%). Conversely, the lack of an increase in cardiac output with passive leg raising identified patients unlikely to be fluid responsive (negative LR, 0.13 [95% CI, 0.07-0.22]; pooled sensitivity, 88%).Passive leg raising followed by measurement of cardiac output or related parameters may be the most useful test for predicting fluid responsiveness in hemodynamically unstable adults. The usefulness of respiratory variation in the vena cava requires confirmatory studies.
A7.14 <i>IRF5</i>Polymorphisms in Systemic Sclerosis
Authors: C Stock, H Sato, C Fonseca, AU Wells, CP Denton, DJ Abraham, G Lindahl, EA Renzoni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Introduction</h3> The transcription factor interferon regulatory factor 5 (IRF-5) plays a key role in the Toll-like receptor signalling pathway, and activation of the type I interferon response. As well as being associated with a number of other rheumatological diseases, including systemic lupus erythematosus and rheumatoid arthritis, <i>IRF5</i> has been identified as a candidate gene for systemic sclerosis (SSc) in a number of genome wide association studies. Although this finding has been replicated in several different studies, there has been variation in the single nucleotide polymorphisms (SNPs) tested, thereby making it difficult to determine which <i>IRF5</i> SNP(s) may be playing a role in susceptibility to SSc. We therefore tested a number of <i>IRF5</i> SNPs in a UK based population with the aim of elucidating the true causal variant(s). <h3>Materials and Methods</h3> To investigate involvement of this gene in susceptibility to SSc, UK Caucasian patients and controls (SSc n = 465, controls n = 416) were genotyped using commercially available TaqMan assays. The <i>IRF5</i> SNPs Rs4728142, Rs2004640, Rs10954213, and Rs10488631, previously reported to be associated with SSc, were selected for investigation. The presence of pulmonary fibrosis was defined as a forced vital capacity &lt;75% and/or the presence of fibrosis on chest imaging. <h3>Results</h3> The allele frequencies of each of the four <i>IRF5</i> SNPs were not significantly different (using Bonferroni correction for multiple testing) in the healthy controls and patients with SSc (Rs4728142: 0.52/0.50, Rs2004640: 0.56/0.60, Rs10954213: 0.37/0.35, Rs10488631: 0.12/0.14). There was also no significant difference found for any of the SNPs when the SSc patients were subdivided according to disease type (limited/diffuse), presence of pulmonary fibrosis, or auto-antibody type. <h3>Conclusions</h3> In contrast to previously published studies we did not detect a significant difference in allele frequency between patients with SSc and healthy control individuals for any of the four <i>IRF5</i> SNPs tested. However, due to the modest cohort sizes available, this study has limited power and therefore may have been unable to detect allele frequency differences with small effects. This study therefore will be repeated with larger cohorts in order to validate these results.